Search

Your search keyword '"Taylor, Maxine"' showing total 39 results
Start Over Author "Taylor, Maxine"
39 results on '"Taylor, Maxine"'

1. Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study

Author

Sutanto, Inge, Soebandrio, Amin, Ekawati, Lenny L, Chand, Krisin, Noviyanti, Rintis, Satyagraha, Ari Winasti, Subekti, Decy, Santy, Yulia Widya, Crenna-Darusallam, Chelzie, Instiaty, Instiaty, Budiman, Waras, Prasetya, Catur Bidik, Lardo, Soroy, Elyazar, Iqbal, Duparc, Stephan, Cedar, Eve, Rolfe, Katie, Fernando, Disala, Berni, Alessandro, Jones, Siôn, Kleim, Jörg-Peter, Fletcher, Kim, Sharma, Hema, Martin, Ana, Taylor, Maxine, Goyal, Navin, Green, Justin A, Tan, Lionel K, and Baird, J Kevin

Published
2023
Full Text
View/download PDF

3. A pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine case study.

Author

Bachhav, Sagar S., Taylor, Maxine, Martin, Ana, Green, Justin A., Duparc, Stephan, Rolfe, Katie, Sharma, Hema, Tan, Lionel K., and Goyal, Navin

Subjects
*BIOAVAILABILITY, *CAPILLARIES, *BLOOD volume, *CORD blood, *SAMPLING (Process), *PHARMACOKINETICS, *BODY weight
Abstract

Aim: Microsampling has the advantage of smaller blood sampling volume and suitability in vulnerable populations compared to venous sampling in clinical pharmacokinetics studies. Current regulatory guidance requires correlative studies to enable microsampling as a technique. A post hoc population pharmacokinetic (POPPK) approach was utilized to investigate blood capillary microsampling as an alternative to venous sampling. Methods: Pharmacokinetic data from microsampling and venous sampling techniques during a paediatric study evaluating tafenoquine, a single‐dose antimalarial for P. vivax, were used. Separate POPPK models were developed and validated based on goodness of fit and visual predictive checks, with pharmacokinetic data obtained via each sampling technique. Results: Each POPPK model adequately described tafenoquine pharmacokinetics using a two‐compartment model with body weight based on allometric scaling of clearance and volume of distribution. Tafenoquine pharmacokinetic parameter estimates including clearance (3.4 vs 3.7 L/h) were comparable across models with slightly higher interindividual variability (38.3% vs 27%) in capillary microsampling‐based data. A bioavailability/bioequivalence comparison demonstrated that the point estimate (90% CI) of capillary microsample versus venous sample model‐based individual post hoc estimates for area under the concentration‐time curve from time zero to infinity (AUC0‐inf) (100.7%, 98.0‐103.5%) and Cmax (79.7%, 76.9‐82.5%) met the 80‐125% and 70‐143% criteria, respectively. Overall, both POPPK models led to the same dose regimen recommendations across weight bins based on achieving target AUC. Conclusions: This analysis demonstrated that a POPPK approach can be employed to assess the performance of alternative pharmacokinetic sampling techniques. This approach provides a robust solution in scenarios where variability in pharmacokinetic data collected via venous sampling and microsampling may not result in a strong linear relationship. The findings also established that microsampling techniques may replace conventional venous sampling methods. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

5. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

Author

Vélez, Iván D, primary, Hien, Tran T, additional, Green, Justin A, additional, Martin, Ana, additional, Sharma, Hema, additional, Rousell, Victoria M, additional, Breton, John J, additional, Ernest, Terry B, additional, Rolfe, Katie, additional, Taylor, Maxine, additional, Mohamed, Khadeeja, additional, Jones, Siôn W, additional, Chau, Nguyen Hoang, additional, Hoa, Nhu Thi, additional, Duparc, Stephan, additional, Tan, Lionel K, additional, and Goyal, Navin, additional

Published
2022
Full Text
View/download PDF

7. Health and Humanity: Humanities 401 Syllabus.

Author

Snowden, Fraser and Taylor, Maxine

Abstract

A syllabus for the "Health and Humanities" interdisciplinary course at Northwestern State University, Louisiana, is presented. An introduction suggests that with the proliferation of technological advances in the field of health care, there is a need for reconsideration of many moral, ethical, legal, and humanistic questions. Information is presented on course objectives and requirements, texts, and grading. Topics, specific objectives, reading assignments, class organization, and discussion questions are given for the following courses: an introduction to the humanities; an overview of the many faces of health and disease; myths, models, and metaphors of health and disease; madness in historical perspective; the impact of scientific thought on the way we define ourselves; values clarification in nursing; stereotypes regarding age and sex; rights and needs of sexual minorities; cultural diversity in nursing practice; a humanistic approach to traditional medicine; the experience of illness; facing death; and the human response to epidemics. For some of these topics, bibliographies are included on monthly magazines, books, basic texts, journals, and other recommended readings. (SW)

Published
1979

8. Evaluation of a Three-Dimensional Primary Human Hepatocyte Spheroid Model: Adoption and Industrialization for the Enhanced Detection of Drug-Induced Liver Injury

Author

Schofield, Christopher A., primary, Walker, Tracy M., additional, Taylor, Maxine A., additional, Patel, Metul, additional, Vlachou, Denise F., additional, Macina, Justyna M., additional, Vidgeon-Hart, Martin P., additional, Williams, Ann, additional, McGill, Paul J., additional, Newman, Carla F., additional, and Sakatis, Melanie Z., additional

Published
2021
Full Text
View/download PDF

13. Gender-based wage differentials among registered dietitians

Author

Pollard, Prudence, Taylor, Maxine, and Daher, Noha

Subjects
Dietitians -- Compensation and benefits, Health care industry -- Human resource management, Compensation management -- Research, Gender equality -- Research, Health care industry, Company personnel management, Business
Published
2007

14. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivaxmalaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

Author

Vélez, Iván D, Hien, Tran T, Green, Justin A, Martin, Ana, Sharma, Hema, Rousell, Victoria M, Breton, John J, Ernest, Terry B, Rolfe, Katie, Taylor, Maxine, Mohamed, Khadeeja, Jones, Siôn W, Chau, Nguyen Hoang, Hoa, Nhu Thi, Duparc, Stephan, Tan, Lionel K, and Goyal, Navin

Abstract

Single-dose tafenoquine 300 mg is approved for Plasmodium vivaxmalaria relapse prevention in patients at least 16 years old. We aimed to determine appropriate oral tafenoquine paediatric dosing regimens, including a dispersible formulation, and evaluated tafenoquine efficacy and safety in children infected with P vivax.

Published
2022
Full Text
View/download PDF

17. MOESM2 of Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Author

Jean, Pamela St, Zhengyu Xue, Carter, Nick, Koh, Gavin, Duparc, Stephan, Taylor, Maxine, Beaumont, Claire, Llanos-Cuentas, Alejandro, Ronnatrai Rueangweerayut, Srivicha Krudsood, Green, Justin, and Rubio, Justin

Abstract

Additional file 2. The percentage of intermediate metabolizers by treatment. The percentage of subjects who were intermediate metabolizers (IM) with error bars representing the standard error of the mean.

Published
2016
Full Text
View/download PDF

18. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial

Author

Barwell, Jamie R., Davies, Colin E., Deacon, Jane, Harvey, Kate, Minor, Julia, Sassano, Antonio, Taylor, Maxine, Usher, Jenny, Wakely, Clare, Earnshaw, Jonathan J., Heather, Brian P., Mitchell, David C., Whyman, Mark R., and Poskitt, Keith R.

Subjects
Ulcers -- Care and treatment, Ulcers -- Research, Varicose ulcer -- Care and treatment, Varicose ulcer -- Research
Published
2004

19. Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects

Author

Green, Justin A., primary, Mohamed, Khadeeja, additional, Goyal, Navin, additional, Bouhired, Samia, additional, Hussaini, Azra, additional, Jones, Siôn W., additional, Koh, Gavin C. K. W., additional, Kostov, Ivan, additional, Taylor, Maxine, additional, Wolstenholm, Allen, additional, and Duparc, Stephan, additional

Published
2016
Full Text
View/download PDF

20. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Author

St Jean, Pamela L., primary, Xue, Zhengyu, additional, Carter, Nick, additional, Koh, Gavin C. K. W., additional, Duparc, Stephan, additional, Taylor, Maxine, additional, Beaumont, Claire, additional, Llanos-Cuentas, Alejandro, additional, Rueangweerayut, Ronnatrai, additional, Krudsood, Srivicha, additional, Green, Justin A., additional, and Rubio, Justin P., additional

Published
2016
Full Text
View/download PDF

21. Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P1 Agonists

Author

Taylor, Simon J., primary, Demont, Emmanuel H., additional, Gray, James, additional, Deeks, Nigel, additional, Patel, Aarti, additional, Nguyen, Dung, additional, Taylor, Maxine, additional, Hood, Steve, additional, Watson, Robert J., additional, Bit, Rino A., additional, McClure, Fiona, additional, Ashall, Holly, additional, and Witherington, Jason, additional

Published
2015
Full Text
View/download PDF

25. Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds

Author

Sakatis, Melanie Z., primary, Reese, Melinda J., additional, Harrell, Andrew W., additional, Taylor, Maxine A., additional, Baines, Ian A., additional, Chen, Liangfu, additional, Bloomer, Jackie C., additional, Yang, Eric Y., additional, Ellens, Harma M., additional, Ambroso, Jeffrey L., additional, Lovatt, Cerys A., additional, Ayrton, Andrew D., additional, and Clarke, Stephen E., additional

Published
2012
Full Text
View/download PDF

28. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2

Author

Blackie, Josie A., primary, Bloomer, Jackie C., additional, Brown, Murray J.B., additional, Cheng, Hung-Yuan, additional, Hammond, Beverley, additional, Hickey, Deirdre M.B., additional, Ife, Robert J., additional, Leach, Colin A., additional, Lewis, V.Ann, additional, Macphee, Colin H., additional, Milliner, Kevin J., additional, Moores, Kitty E., additional, Pinto, Ivan L., additional, Smith, Stephen A., additional, Stansfield, Ian G., additional, Stanway, Steven J., additional, Taylor, Maxine A., additional, and Theobald, Colin J., additional

Published
2003
Full Text
View/download PDF

29. The discovery of SB-435495

Author

Blackie, Josie A., primary, Bloomer, Jackie C., additional, Brown, Murray J.B., additional, Cheng, Hung-Yuan, additional, Elliott, Richard L., additional, Hammond, Beverley, additional, Hickey, Deirdre M.B., additional, Ife, Robert J., additional, Leach, Colin A., additional, Lewis, V.Ann, additional, Macphee, Colin H., additional, Milliner, Kevin J., additional, Moores, Kitty E., additional, Pinto, Ivan L., additional, Smith, Stephen A., additional, Stansfield, Ian G., additional, Stanway, Steven J., additional, Taylor, Maxine A., additional, Theobald, Colin J., additional, and Whittaker, Caroline M., additional

Published
2002
Full Text
View/download PDF

30. 1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A 2

Author

Bloomer, Jackie C., primary, Boyd, Helen F., additional, Hickey, Deirdre M.B., additional, Ife, Robert J., additional, Leach, Colin A., additional, Macphee, Colin H., additional, Milliner, Kevin J., additional, Pinto, Ivan L., additional, Rawlings, D.Anthony, additional, Smith, Stephen A., additional, Stansfield, Ian G., additional, Stanway, Steven J., additional, Taylor, Maxine A., additional, Theobald, Colin J., additional, and Whittaker, Caroline M., additional

Published
2001
Full Text
View/download PDF

33. Information exchange

Author

Duff, Lesley, primary, Stokes, Jacqueline, additional, Taylor, Maxine, additional, Cranston, Audrey, additional, Cook, Jacqueline, additional, Heffer, Margaret, additional, and George V, King, additional

Published
1991
Full Text
View/download PDF

34. Disposition and Metabolism of Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Humans

Author

Dave, Mehul, Nash, Mike, Young, Graeme C., Ellens, Harma, Magee, Mindy H., Roberts, Andrew D., Taylor, Maxine A., Greenhill, Robert W., and Boyle, Gary W.

Abstract

The absorption, metabolism, and excretion of darapladib, a novel inhibitor of lipoprotein-associated phospholipase A2, was investigated in healthy male subjects using [14C]-radiolabeled material in a bespoke study design. Disposition of darapladib was compared following single i.v. and both single and repeated oral administrations. The anticipated presence of low circulating concentrations of drug-related material required the use of accelerator mass spectrometry as a sensitive radiodetector. Blood, urine, and feces were collected up to 21 days post radioactive dose, and analyzed for drug-related material. The principal circulating drug-related component was unchanged darapladib. No notable metabolites were observed in plasma post-i.v. dosing; however, metabolites resulting from hydroxylation (M3) and N-deethylation (M4) were observed (at 4%–6% of plasma radioactivity) following oral dosing, indicative of some first-pass metabolism. In addition, an acid-catalyzed degradant (M10) resulting from presystemic hydrolysis was also detected in plasma at similar levels of ∼5% of radioactivity post oral dosing. Systemic exposure to radioactive material was reduced within the repeat dose regimen, consistent with the notion of time-dependent pharmacokinetics resulting from enhanced clearance or reduced absorption. Elimination of drug-related material occurred predominantly via the feces, with unchanged darapladib representing 43%–53% of the radioactive dose, and metabolites M3 and M4 also notably accounting for ∼9% and 19% of the dose, respectively. The enhanced study design has provided an increased understanding of the absorption, distribution, metabolism and excretion (ADME) properties of darapladib in humans, and substantially influenced future work on the compound.

Published
2014
Full Text
View/download PDF

35. Diversifying from a one-industry economy.

Author

Taylor, Maxine

Subjects
Economic development -- Analysis, Economic policy -- Analysis, Diversification in industry -- Analysis, Washington -- Economic policy
Abstract

Washington State's economy has been feeling the impact of recent environmental legislation as a result of a long time dependence in many areas on a single-source economic base. Timber communities [...]

Published
1994

36. Prologue to imperialism :

Author

Taylor, Maxine Powell,

Subjects
History, European.
Abstract

A subsidiary theme in this work concerns the relationship of the Geographical Society of Paris with the expansionists. The Society became a kind of clearinghouse for various views and publications, and it furnished a "secure" forum for expansionist-minded men who ranked high in the government.

Published
1980

37. How I see it.

Author

Taylor, Maxine

Subjects
SAVINGS & loan associations, THRIFT institutions, BRITISH banking industry, INTEREST rates
Abstract

The author comments on the challenges facing building societies in Great Britain. She relates the distinction of the business model of building societies from the business model of banks. The author expects profits to be negatively affected in the context of a sustained low interest rate environment. She believes that banks and mutuals will continue to face challenges since they have a strong retail funding component.

Published
2009

38. The discovery of SB-435495: A potent, orally active inhibitor of lipoprotein-Associated phospholipase A2 for evaluation in man

Author

Blackie, Josie A., Bloomer, Jackie C., Brown, Murray J. B., Cheng, Hung-Yuan, Elliott, Richard L., Hammond, Beverley, Hickey, Deirdre M. B., Ife, Robert J., Leach, Colin A., Lewis, V. Ann, Macphee, Colin H., Milliner, Kevin J., Moores, Kitty E., Pinto, Ivan L., Smith, Stephen A., Stansfield, Ian G., Stanway, Steven J., Taylor, Maxine A., Theobald, Colin J., and Whittaker, Caroline M.

Subjects
*LIPOPROTEINS, *PHOSPHOLIPASE A2
Abstract

The introduction of a functionalised amido substituent into a series of 1-(biphenylmethylacetamido)-pyrimidones has given a series of inhibitors of recombinant lipoprotein-associated phospholipase A2 with sub-nanomolar potency and very encouraging developability properties. Diethylaminoethyl derivative 32, SB-435495, was selected for progression to man. [Copyright &y& Elsevier]

Published
2002
Full Text
View/download PDF

39. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial.

Author

Gohel MS, Barwell JR, Taylor M, Chant T, Foy C, Earnshaw JJ, Heather BP, Mitchell DC, Whyman MR, and Poskitt KR

Subjects
Aged, Aged, 80 and over, Chronic Disease, Combined Modality Therapy methods, Disease-Free Survival, Female, Humans, Male, Middle Aged, Secondary Prevention, Treatment Outcome, Wound Healing, Stockings, Compression, Varicose Ulcer therapy, Vascular Surgical Procedures methods
Abstract

Objective: To determine whether recurrence of leg ulcers may be prevented by surgical correction of superficial venous reflux in addition to compression., Design: Randomised controlled trial., Setting: Specialist nurse led leg ulcer clinics in three UK vascular centres., Participants: 500 patients (500 legs) with open or recently healed leg ulcers and superficial venous reflux., Interventions: Compression alone or compression plus saphenous surgery., Main Outcome Measures: Primary outcomes were ulcer healing and ulcer recurrence. The secondary outcome was ulcer free time., Results: Ulcer healing rates at three years were 89% for the compression group and 93% for the compression plus surgery group (P=0.73, log rank test). Rates of ulcer recurrence at four years were 56% for the compression group and 31% for the compression plus surgery group (P<0.01). For patients with isolated superficial reflux, recurrence rates at four years were 51% for the compression group and 27% for the compress plus surgery group (P<0.01). For patients who had superficial with segmental deep reflux, recurrence rates at three years were 52% for the compression group and 24% for the compression plus surgery group (P=0.04). For patients with superficial and total deep reflux, recurrence rates at three years were 46% for the compression group and 32% for the compression plus surgery group (P=0.33). Patients in the compression plus surgery group experienced a greater proportion of ulcer free time after three years compared with patients in the compression group (78% v 71%; P=0.007, Mann-Whitney U test)., Conclusion: Surgical correction of superficial venous reflux in addition to compression bandaging does not improve ulcer healing but reduces the recurrence of ulcers at four years and results in a greater proportion of ulcer free time., Trial Registration: Current Controlled Trials ISRCTN07549334 [controlled-trials.com].

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results